ASX News

Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent

Melbourne (Australia) and Brussels (Belgium) – 19 April 2021. Telix announces the launch of the international NOBLE Registry of Telix’s ‘rest of world’ prostate cancer imaging agent and the dosing of the first patient

Telix is delighted to announce the launch of the international NOBLE Registry of Telix’s ‘rest of world’ prostate cancer imaging agent TLX599-CDx (99mTc-HYNIC-iPSMA), and the dosing of the first patient at the University College Hospital, Ibadan (Nigeria).

The aim of the NOBLE (Nobody Left Behind) Registry is to collect data on the clinical use of TLX599-CDx, a ‘sibling’ asset to Illuccix® (TLX591-CDx, Kit for the preparation of 68Ga-PSMA-11 injection). TLX599-CDx is an investigational product being developed by Telix to facilitate patient access to advanced prostate cancer imaging in countries where single photon emission computed tomography (SPECT) imaging is predominant in healthcare facilities. Whereas Illuccix® utilises positron emission tomography (PET), TLX599-CDx employs SPECT, a diagnostic imaging technology that is widely available in healthcare facilities throughout the world.

The NOBLE Registry is led by Principal Investigator Dr. Batool Albalooshi, Head of Nuclear Medicine and Molecular Imaging at the Dubai Health Authority, United Arab Emirates, and is co-supported by Telix and the Brussels-based Oncidium Foundation.

The NOBLE Registry will collect prospective, real-world clinical data on the use of TLX599-CDx from a consortium of sites in eight countries, including Australia.

Each site will conduct its own investigator-initiated clinical study of TLX599-CDx under a common protocol and will share resulting data with the NOBLE Registry. Data collected will include use of TLX599-CDx for the diagnostic imaging of patients with prostate cancer, from initial disease staging in newly diagnosed patients, through to the later stages of advanced disease. Telix anticipates that this real-world data will facilitate the design of future formal registration clinical trials of TLX599-CDx.

Telix Chief Executive Officer Dr. Christian Behrenbruch stated, “We are honoured to support the launch of the NOBLE Registry, which represents the very essence of our belief that every patient deserves access to the benefits of nuclear medicine. Telix is committed to providing access to advanced prostate cancer imaging to all men across the globe and it is fitting that this excellent technology, developed at the Instituto Nacional de Investigaciones Nucleares (ININ, Mexico), will play a part in delivering this objective. We wish to thank the Oncidium Foundation for their support and partnership, as well as the expert global clinical leadership team led by Dr. Albalooshi. Above all, we are grateful to the patients that will make this registry study possible and, in doing so, help to deliver an important milestone toward improving access to this important technology.”

NOBLE Registry committee Chair Dr. Batool Albalooshi said, “The advancement of PSMA directed diagnostics and therapeutics in prostate cancer is helping to extend life and improve treatment outcomes in men with prostate cancer. However, millions of men do not have access to PET imaging. For this reason, it is our aspiration to develop a powerful, affordable, and widely available alternative imaging tool by using iPSMA-SPECT technology.”

To read the ASX disclosure please click here.

To return to our homepage please click here.

More Articles

Corporate Spotlight

Telix at ANZSNM Annual Scientific Meeting

13 May 2021 – Clinical Spotlight | Telix to Sponsor Pre-Conference Symposium at 51st Australian and New Zealand Society of...

ASX News

Telix Pharmaceuticals Limited AGM 2021 – Chairman and CEO Addresses

Melbourne (Australia) 12 May 2021 – Telix provides the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting...

ASX News

Telix and Monrol Expand Alliance to Include Lutetium Supply

Melbourne (Australia) and Istanbul (Turkey) – 11 May 2021. Telix announces global clinical supply agreement with Monrol for the supply...

ASX News

Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy

Melbourne (Australia) – 10 May 2021. Telix has been granted HREC approval and received CTN clearance by the TGA to...

ASX News

Telix Announces Executive Leadership Appointments and Establishment of Asia Pacific Operating Region

Melbourne (Australia) – 3 May 2021. Telix announces several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC)...

ASX News

Telix Pharmaceuticals Appoints Richard Valeix as EMEA President

Melbourne (Australia) and Herstal (Belgium) – 3 May 2021. Telix announces Richard Valeix has joined the Telix executive leadership team...

ASX News

Telix Pharmaceuticals and Global Medical Solutions Complete Strategic Manufacturing Agreement

Melbourne (Australia) and Henderson, NV (U.S.A.) – 27 April 2021. Telix announces it has completed a strategic manufacturing agreement with...

ASX News

Japanese Renal Cancer Imaging Trial Meets Study Objectives

Melbourne (Australia) and Kyoto (Japan) – 21 April 2021. Telix announces the Company’s ZIRDAC-JP study of its renal cancer imaging...

ASX News

Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent

Melbourne (Australia) and Brussels (Belgium) – 19 April 2021. Telix announces the launch of the international NOBLE Registry of Telix’s...

ASX News

Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021

Melbourne (Australia) – 12 April 2021. Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12...

ASX News

Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 31st March 2021. Telix announces it has completed an agreement with Grand River...

Corporate Spotlight

Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

29th March 2021 – Corporate Spotlight | Darren Patti joins Telix as Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

ASX News

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial supply...

Corporate Spotlight

Telix Appoints Sébastien Linard as General Manager, Telix European Manufacturing Facility

8th March 2021 – Corporate Spotlight | Sébastien Linard joins Telix as General Manager of Telix’s European Manufacturing in Seneffe,...

ASX News

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial...

ASX News

Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report

Melbourne (Australia) – 26th February 2021. Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual Report.

ASX News

Telix and Kanazawa University Cleared to Commence Prostate Cancer Imaging Study in Japan

Melbourne (Australia) and Kyoto (Japan) – 22nd February 2021. Telix Japan receives Clinical Trial Notification (CTN) clearance to commence a...

ASX News

Telix FY2020 Results and Company Update Conference Call

Melbourne (Australia) – 16th February 2021. Telix to present the Company’s FY2020 results together with an update on Telix’s operations.

ASX News

Czech Republic Grants National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product

Melbourne (Australia) and Liège (Belgium) – 16th February 2021. Telix announces the Ministry of Health of the Czech Republic is...

ASX News

Telix and Heidelberg University Hospital to Develop Next Generation Theranostics

Melbourne (Australia) and Heidelberg (Germany) – 10th February 2021. Telix announces research cooperation agreement with Heidelberg University Hospital to develop...

Corporate Spotlight

Industry Leaders’ Round-Table at SNMMI Mid-Winter Satellite Symposium

3rd February 2021 | Corporate Spotlight – Recording of Industry Leaders’ Round-Table Discussion at SNMMI Mid-Winter Symposium: Ga-68 PSMA-11: Advances...

ASX News

First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 25th January 2021. Telix Pharmaceuticals announces the first U.S. patients have been dosed...

Corporate Spotlight

ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target

Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer...

ASX News

Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product

Melbourne (Australia) and Indianapolis, IN (USA) – 16th December 2020. Telix has filed a New Drug Submission (NDS) with Health Canada...

ASX News

Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance

Melbourne (Australia) – 16th December 2020. [Article updated with new video 16th February 2021] Telix Pharmaceuticals announces collaboration with Mauna...

ASX News

Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging

Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration...

ASX News

Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data

Melbourne (Australia) – 14th December 2020. Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an...

ASX News

Telix Granted TGA Priority Review for Prostate Cancer Imaging

Melbourne (Australia) – 7th December 2020. Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the...

ASX News

Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging

Melbourne (Australia) and Seoul (South Korea) – 3rd December 2020. Telix Pharmaceuticals announces it has entered into a licensing and partnership...